News

Phase 3 Trial Planned for PBI-4050, Potential Treatment for Mild-to-Moderate IPF Patients

A pivotal Phase 3 trial evaluating PBI-4050, a potential treatment of idiopathic pulmonary fibrosis, will be open to all patients with mild-to-moderate IPF regardless of whether they are also taking Ofev (nintedanib) or not, the therapy’s developer, Prometic Life Sciences, announced. The trial, in other words, will evaluate the efficacy and safety of…

Gentiopicroside Effectively Fights Lung Fibrosis, Chinese Mouse Study Finds

A natural compound called gentiopicroside effectively lowers inflammation and tissue scarring in a mouse model of pulmonary fibrosis (PF), say researchers at China’s Kunming Medical University. Since the plant-derived compound targets both fibrotic and inflammatory processes, researchers suggested it may be an ideal drug candidate for lung fibrosis — particularly…

Three Lakes Partners Announces Winners of IPF Catalyst Challenge

Advanced Interactive Response Systems (AIRS), Owlstone Medical and patientMpower are the three winners of the $1 million IPF Catalyst Challenge presented by Three Lakes Partners, a philanthropy organization financing research of idiopathic pulmonary fibrosis (IPF). The three winners will receive $333,333 each to develop their projects. Level Ex received the competition’s Audience…

PatientMpower Among Finalists for $1 Million in IPF Catalyst Challenge

The IPF Catalyst Challenge is being held in Chicago, Illinois today as nine finalists make their final pitch in a competition for $1 million in funding for innovative, meaningful solutions to improve the quality of life for people living with idiopathic pulmonary fibrosis (IPF). Among the finalists is patientMpower, a…